Three new studies have launched in Manchester to evaluate the effectiveness of vaccines for severe acute respiratory infections. The trials are the first to be delivered by the Greater Manchester Commercial Research Delivery Centre (GM CRDC), supported by the National Institute for Health and Care Research.
The studies aim to recruit 300 patients hospitalised with severe acute respiratory infections during the 2024–2025 winter season. They will assess how COVID-19 and respiratory syncytial virus (RSV) vaccines perform outside clinical trials and across diverse populations.
Dr Shazaad Ahmad, Principal Investigator for the studies in Greater Manchester, said: “Vaccination remains one of the most effective interventions for preventing severe outcomes, reducing hospital admissions, and protecting the most vulnerable.”
He added: “These real-world evaluations will help ensure that vaccination programmes deliver maximum benefit to the populations they are designed to protect.”
The GM CRDC is one of 21 centres established in April 2025 to accelerate commercial clinical research across the UK. Hosted by Manchester University NHS Foundation Trust, it builds on the region’s research expertise to position Manchester as a hub for pioneering trials.
Dr Claire Cole, Director of NIHR GM CRDC, said: “This is a fantastic milestone for the GM CRDC and demonstrates our ability to facilitate the rapid establishment of cutting-edge clinical trials in Greater Manchester.”
She added: “Studies like this strengthen our commercial partnerships bringing jobs and investment as well as growing Greater Manchester’s status as a clinical research powerhouse.”
The studies were set up just 29 days after the GM CRDC was invited to participate. They form part of id.DRIVE, a public-private partnership supporting observational research into infectious diseases and related interventions across the UK and Europe.
